Multiselective Recognition of Metal Ion-Nucleic Acid Complexes by CRISPR/Cas12a and Quantum Dots Enables the Profiling of Circulating Tumor DNA in Breast Cancer
A novel blood test detects breast cancer mutations with near-perfect accuracy, potentially enabling faster staging through routine plasma samples.
A novel label-free CRISPR/Cas12a assay leveraging a grape-cluster rolling circle amplification nanomaterial detects PIK3CA mutation ctDNA with attomolar sensitivity and 100% specificity in breast cancer plasma. Validated in 42 clinical samples with AUC 0.978 for staging, this platform demonstrates significant translational potential as a rapid, enzyme-free liquid biopsy tool.
What the study was
- Study design
- Diagnostic validation study (clinical plasma samples)
- Population
- Breast cancer patients (42 clinical plasma samples)
- Sample size
- 42
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Analytical Chemistry
Why it surfaced
Mechanistically novel CRISPR-based ctDNA detection with impressive sensitivity/specificity in clinical samples; small n=42 limits evidence maturity but strong technical validation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.